Cellectis S.A. (NASDAQ:CLLS) Sees Significant Drop in Short Interest

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 395,400 shares, a decline of 10.3% from the July 31st total of 440,700 shares. Based on an average daily volume of 53,700 shares, the short-interest ratio is presently 7.4 days.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Oppenheimer cut their price objective on shares of Cellectis from $11.00 to $10.00 and set an "outperform" rating for the company in a report on Wednesday, June 12th. JMP Securities reaffirmed a "market outperform" rating and issued a $6.00 price target on shares of Cellectis in a report on Friday, May 31st. Finally, StockNews.com started coverage on Cellectis in a research note on Sunday, August 25th. They set a "sell" rating on the stock.

Institutional Investors Weigh In On Cellectis

Large investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its stake in Cellectis by 6.2% in the first quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company's stock valued at $1,125,000 after purchasing an additional 24,906 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company's stock valued at $2,192,000 after buying an additional 10,605 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Cellectis during the 2nd quarter valued at $29,000. Finally, Long Focus Capital Management LLC lifted its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after acquiring an additional 130,000 shares during the last quarter. Institutional investors own 63.90% of the company's stock.

Cellectis Stock Performance

Shares of CLLS stock remained flat at $2.40 during trading hours on Friday. 15,229 shares of the stock were exchanged, compared to its average volume of 33,203. The stock has a 50 day simple moving average of $2.11 and a two-hundred day simple moving average of $2.47. The firm has a market capitalization of $133.39 million, a price-to-earnings ratio of -1.86 and a beta of 3.10. Cellectis has a one year low of $0.96 and a one year high of $3.77. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05. The firm had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. As a group, equities research analysts anticipate that Cellectis will post -0.54 EPS for the current fiscal year.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.